NASDAQ:CBLI - Cleveland BioLabs Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.71 -0.10 (-5.52 %) (As of 12/16/2018 04:00 PM ET)Previous Close$1.71Today's Range$1.71 - $1.871052-Week Range$1.54 - $4.25Volume4,479 shsAverage Volume7,355 shsMarket Capitalization$19.32 millionP/E RatioN/ADividend YieldN/ABeta-0.31 ProfileDiscussionChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Its development programs include CBLB612, which is in preclinical studies, a synthetic molecule that activates the toll-like heterodimeric receptor 2/6 and stimulated white blood cell generation; and that has completed Phase II for treating myelosuppressive prophylaxis in patients with breast cancer receiving doxorubicin-cyclophosphamide chemotherapy. The company is also developing Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. Cleveland BioLabs, Inc. has strategic partnerships with the Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York. Receive CBLI News and Ratings via Email Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CBLI Previous Symbol CUSIPN/A Webwww.cbiolabs.com Phone716-849-6810 Debt Debt-to-Equity RatioN/A Current Ratio3.54 Quick Ratio3.54 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.95 million Price / Sales9.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book2.59 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,700,000.00 Net Margins-245.29% Return on Equity-75.80% Return on Assets-56.63% Miscellaneous Employees19 Outstanding Shares11,300,000Market Cap$19.32 million OptionableNot Optionable Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions What is Cleveland BioLabs' stock symbol? Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI." How were Cleveland BioLabs' earnings last quarter? Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter. The biotechnology company had revenue of $0.28 million for the quarter. Cleveland BioLabs had a negative net margin of 245.29% and a negative return on equity of 75.80%. View Cleveland BioLabs' Earnings History. When is Cleveland BioLabs' next earnings date? Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Cleveland BioLabs. Has Cleveland BioLabs been receiving favorable news coverage? News articles about CBLI stock have trended positive on Sunday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cleveland BioLabs earned a news impact score of 3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the immediate future. Who are some of Cleveland BioLabs' key competitors? Some companies that are related to Cleveland BioLabs include Senomyx (SNMX), HedgePath Pharmaceuticals (HPPI), Dyadic International (DYAI), BIOQUAL (BIOQ), Vitality Biopharma (VBIO), Bioanalytical Systems (BASI), US Stem Cell (USRM), Geovax Labs (GOVX), ALGAE TEC LTD/S (ALGXY), Protalex (PRTX), Tenax Therapeutics (TENX), Eloxx Pharmaceuticals (ELOX), Intrexon (XON), National Research (NRCIB) and National Research (NRCIA). Who are Cleveland BioLabs' key executives? Cleveland BioLabs' management team includes the folowing people: Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 64)Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 62)Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory AffairsDr. Andrei Purmal Ph.D., VP of Chemistry How do I buy shares of Cleveland BioLabs? Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cleveland BioLabs' stock price today? One share of CBLI stock can currently be purchased for approximately $1.71. How big of a company is Cleveland BioLabs? Cleveland BioLabs has a market capitalization of $19.32 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe. What is Cleveland BioLabs' official website? The official website for Cleveland BioLabs is http://www.cbiolabs.com. How can I contact Cleveland BioLabs? Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected] MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 106 (Vote Outperform)Underperform Votes: 88 (Vote Underperform)Total Votes: 194MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?